As part of the agreement, Canadian urologists will be able to order PCMT through CML HealthCare in early 2013.
PCMT by applying mitochondrial DNA analysis to tissue samples from the first prostate biopsy, detects the presence of malignant cells to assist in the diagnosis and management of prostate cancer and eliminates the need for a subsequent biopsy.
CML HealthCare president and chief executive officer Thomas Wellner said, ”CML HealthCare is proud to offer this advanced diagnostic to assist urologists across Canada with their diagnosis and management of prostate cancer."
Mitomics president and chief executive officer Robert Poulter said, "This agreement is aligned with our commercial strategy to provide broad access to PCMT and further validates the strong demand from physicians to improve the diagnosis of prostate cancer for patients."